Atlantic Coast Acquisition Corp. Warrants (ABPWW)
OTC PINK OTC PINK Primary Summary
Atlantic Coast Acquisition Corp. Warrants Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TC Thomas Cagna Sandia Investment Management LP | 358,427 | $22,401.69 | - | -$22,401.69 | -100% |
| BO Brian Oliveira Clear Street Group Inc. | 376,785 | $8,892.01 | - | -$8,892.01 | -100% |
Atlantic Coast Acquisition Corp. Warrants (ABPWW) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Atlantic Coast Acquisition Corp. Warrants ever had a stock split?
Atlantic Coast Acquisition Corp. Warrants Profile
| Biotechnology Industry | Healthcare Sector | Jin Wook Suk CEO | OTC PINK Exchange | 000847111 CUSIP |
| US Country | 6 Employees | - Last Dividend | - Last Split | 7 Mar 2022 IPO Date |
Overview
Abpro Holdings, Inc. stands out in the biotechnology industry by focusing on the development of antibody therapeutics aimed at addressing critical health issues in immuno-oncology, ophthalmology, and autoimmunity. Leveraging its DiversImmune platform, the company tackles a notable bottleneck in the creation of antibody therapeutics. This innovative approach not only positions the company at the cutting edge of medical advances but also showcases its commitment to pioneering solutions for complex medical conditions. Initially known as Abpro Corporation, the entity has undergone a name change to Abpro Holdings, Inc. as of November 2024, signifying a new chapter in its evolution. Founded in 2004 and based in Woburn, Massachusetts, Abpro Holdings, Inc. maintains strategic partnerships with Abpro Bio Co. Ltd and NJCTTQ, further cementing its stance in the biotechnology space.
Products and Services
- ABP-100
As a leading candidate in Abpro Holdings, Inc.'s portfolio, ABP-100 targets the treatment of a variety of cancers including breast, gastric, and colorectal cancers. This therapeutic approach highlights the company's dedication to combating some of the most challenging and prevalent forms of cancer, aiming to provide innovative treatments that can improve the quality of life for patients struggling with these diseases.
- ABP-201
ABP-201 represents another significant stride in Abpro Holdings, Inc.’s commitment to addressing unmet medical needs, specifically focusing on vascular diseases of the eye. This treatment underscores the company's versatile approach to healthcare, extending its reach into ophthalmology and offering hope to patients suffering from vision-threatening conditions.
